Residency · Residency · Respirology

Asthma - Pathophysiology and Stepwise Management

Epidemiology and Disease Burden

Global Prevalence

Asthma is a global public health challenge of immense proportions, affecting approximately 300 million people worldwide with a prevalence that continues to rise, particularly in low- and middle-income countries undergoing rapid urbanization and environmental transition. In developed nations, the lifetime prevalence among adults ranges from 8% to 12%, making asthma one of the most common chronic diseases. The annual global mortality attributed to asthma remains staggering at approximately 455,000 deaths, the vast majority of which are considered preventable with appropriate diagnosis, treatment, and patient education. In North America, the burden of asthma falls disproportionately on Black and Hispanic populations, who experience higher rates of emergency department visits, hospitalizations, and asthma-related mortality compared to White populations. These disparities reflect a complex interplay of genetic susceptibility, environmental exposures, socioeconomic determinants of health, and systemic inequities in healthcare access.

Pathophysiology

Airway Inflammation

The pathophysiology of asthma is anchored in chronic airway inflammation, with the Type 2 (T2) high inflammatory endotype representing the most thoroughly characterized and clinically actionable pathway. T2-high inflammation is orchestrated by a cascade of cytokines, principally interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), produced by Th2 lymphocytes and type 2 innate lymphoid cells (ILC2). Mast cells and eosinophils serve as key effector cells. IL-4 drives immunoglobulin E (IgE) class switching in B cells and promotes Th2 differentiation, establishing the allergic sensitization that characterizes atopic asthma. IL-5 is the principal mediator of eosinophil maturation, recruitment to the airways, and prolonged survival, making it the central target for anti-eosinophilic biologic therapies. IL-13 drives goblet cell metaplasia, mucus hypersecretion, airway smooth muscle hypercontractility, and subepithelial fibrosis, contributing to the structural and functional airway changes that characterize established disease.

Non-T2 inflammation, which encompasses neutrophilic and paucigranulocytic patterns, is driven by distinct mediators including IL-17 and IL-8, and is often resistant to corticosteroid therapy. This endotype is increasingly recognized as a significant contributor to severe asthma and treatment-refractory disease. Upstream of these inflammatory pathways, epithelial alarmins, including thymic stromal lymphopoietin (TSLP), IL-25, and IL-33, are released by damaged airway epithelium in response to environmental insults and serve as master regulators that initiate and amplify the inflammatory cascade. These alarmins have emerged as important therapeutic targets, with tezepelumab (anti-TSLP) representing the first biologic to target this upstream mechanism.

Airway Remodeling

Airway remodeling represents the structural consequence of chronic inflammation and contributes to the fixed airflow limitation observed in long-standing asthma. The pathologic hallmark is subepithelial fibrosis, characterized by collagen deposition below the basement membrane, leading to reticular basement membrane thickening. Airway smooth muscle undergoes both hypertrophy (increased cell size) and hyperplasia (increased cell number), amplifying the bronchoconstrictor response and narrowing the airway lumen. Goblet cell hyperplasia and mucus gland hypertrophy increase mucus production, which can plug small and medium airways, particularly during severe exacerbations. Additional features include angiogenesis within the airway wall and neural remodeling with increased sensory nerve density. Importantly, remodeling can begin early in the disease course, even before clinical diagnosis, and is at least partially irreversible, underscoring the rationale for early and sustained anti-inflammatory treatment.

Airway Hyperresponsiveness (AHR)

Airway hyperresponsiveness, defined as an exaggerated bronchoconstrictor response to a variety of stimuli, is a cardinal feature of asthma. Direct stimuli, such as methacholine and histamine, act directly on airway smooth muscle receptors, while indirect stimuli, including mannitol, hypertonic saline, and exercise, provoke bronchoconstriction through the release of inflammatory mediators from airway cells. Methacholine challenge testing is the most widely used provocative test: a provocative concentration causing a 20% fall in FEV1 (PC20) below 4 mg/mL is highly suggestive of asthma, a value between 4 and 16 mg/mL is considered borderline, and the test has a sensitivity of approximately 95% with a specificity of approximately 80%. The high sensitivity makes a negative methacholine challenge particularly useful for excluding asthma in patients with non-specific symptoms.

<image>A detailed cross-sectional diagram comparing a normal airway with an asthmatic airway. The normal airway shows thin epithelium, minimal subepithelial collagen, relaxed smooth muscle, and a patent lumen. The asthmatic airway shows thickened epithelium with goblet cell hyperplasia, mucus plugging, thickened subepithelial basement membrane with collagen deposition, hypertrophied smooth muscle, inflammatory cell infiltrate (eosinophils in pink, mast cells in purple, Th2 cells in blue), edema, and a narrowed lumen. Include labels for each structural change and inflammatory mediators (IL-4, IL-5, IL-13) with arrows showing their downstream effects.</image>

Diagnosis

Spirometric Criteria

The diagnosis of asthma requires the demonstration of variable expiratory airflow limitation. Spirometry should reveal an FEV1/FVC ratio below the lower limit of normal, along with evidence of reversibility or variability. Bronchodilator reversibility is defined as an increase in FEV1 of at least 200 mL and at least 12% from the pre-bronchodilator baseline following administration of a short-acting beta-agonist. Excessive diurnal variability, defined as peak expiratory flow variation exceeding 10% in adults (or 13% in children), provides supporting evidence. Positive bronchoprovocation testing, with a methacholine PC20 below 4 mg/mL or a positive mannitol challenge, can confirm the diagnosis when spirometric reversibility is not demonstrable at the time of testing.

Biomarkers

Biomarkers play an increasingly important role in asthma diagnosis and phenotyping. Fractional exhaled nitric oxide (FeNO), a marker of eosinophilic airway inflammation, supports the presence of T2 inflammation when elevated above 50 ppb in adults, with values above 25 ppb considered suggestive. Elevated blood eosinophils at or above 300 cells per microliter support a T2 phenotype and predict responsiveness to corticosteroids and anti-eosinophilic biologic therapies. Sputum eosinophilia at or above 3% defines eosinophilic asthma and remains the gold standard for airway eosinophilic assessment, although the technique is labor-intensive and not widely available in routine clinical practice. Total IgE supports atopic status but lacks specificity for asthma diagnosis and is more useful for guiding anti-IgE therapy selection and dosing.

Differential Diagnosis

The differential diagnosis of asthma includes several conditions that can mimic or coexist with the disease. Vocal cord dysfunction, now more accurately termed inducible laryngeal obstruction, presents with inspiratory stridor and produces a characteristic flattened inspiratory loop on the flow-volume loop. COPD, while sharing features of airflow obstruction, typically presents with irreversible obstruction in older patients with significant smoking histories. Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) should be considered in any asthma patient with peripheral eosinophilia and evidence of systemic vasculitis. Allergic bronchopulmonary aspergillosis (ABPA) presents with asthma, bronchiectasis (often central), Aspergillus sensitization, and markedly elevated total IgE.

GINA 2024 Stepwise Management

Track 1: Preferred (ICS-Formoterol Maintenance and Reliever Therapy - MART)

The GINA 2024 guidelines establish ICS-formoterol maintenance and reliever therapy (MART) as the preferred treatment track, reflecting a paradigm shift in asthma management. At Step 1, as-needed low-dose ICS-formoterol (budesonide-formoterol 200/6 mcg as needed) is recommended for patients with infrequent symptoms, replacing the previous SABA-only approach. Step 2 introduces low-dose ICS-formoterol as maintenance therapy (1 puff twice daily) with continued as-needed use. Step 3 escalates to medium-dose ICS-formoterol maintenance (2 puffs twice daily) with as-needed relief. Step 4 adds a long-acting muscarinic antagonist (LAMA), typically tiotropium Respimat 2.5 mcg daily, to medium-dose ICS-formoterol, with consideration of high-dose ICS-formoterol. Step 5 triggers phenotype assessment, biologic therapy evaluation, add-on LAMA, and referral to a severe asthma center for comprehensive management.

Track 2: Alternative (ICS + SABA Reliever)

An alternative track retains the traditional approach using a short-acting beta-agonist as the reliever medication. Step 1 requires low-dose ICS taken whenever SABA is used, ensuring that no patient receives SABA without concomitant anti-inflammatory therapy. Step 2 introduces daily low-dose ICS with as-needed SABA. Step 3 escalates to a low-dose ICS-LABA combination, such as fluticasone/salmeterol, with as-needed SABA. Step 4 employs medium- to high-dose ICS-LABA with LAMA and as-needed SABA. Step 5 management is identical to Track 1.

Key Evidence Base for MART

The MART approach is supported by landmark clinical trials. The SYGMA 1 and SYGMA 2 trials demonstrated that as-needed budesonide-formoterol was non-inferior to regular maintenance ICS for the prevention of exacerbations in mild asthma, while dramatically reducing the total corticosteroid exposure. The PRACTICAL trial went further, demonstrating that as-needed budesonide-formoterol was superior to maintenance ICS plus as-needed SABA for exacerbation prevention in mild-to-moderate asthma. Collectively, these trials led GINA 2024 to the landmark recommendation that SABA-only treatment is no longer recommended at any step of asthma management, marking the end of an era in which SABA was the default first-line therapy.

ICS Dose Equivalents (Adults)

Understanding ICS dose equivalents is essential for appropriate therapy selection and escalation. Low-dose ICS corresponds to budesonide 200-400 mcg/day, fluticasone propionate 100-250 mcg/day, or beclomethasone 200-500 mcg/day. Medium-dose ICS corresponds to budesonide 400-800 mcg/day or fluticasone propionate 250-500 mcg/day. High-dose ICS corresponds to budesonide above 800 mcg/day or fluticasone propionate above 500 mcg/day. The dose-response curve for ICS is relatively flat beyond medium doses, meaning that doubling the ICS dose from medium to high yields diminishing additional anti-inflammatory benefit while increasing the risk of systemic side effects.

<image>A comprehensive stepwise management algorithm for asthma following GINA 2024 guidelines. Display two parallel tracks: Track 1 (MART approach with ICS-formoterol) and Track 2 (traditional approach with SABA reliever). Show 5 steps as ascending blocks for each track, with preferred controllers and relievers at each step. Include a color gradient from green (Step 1) to red (Step 5) indicating increasing severity. Add arrows showing step-up and step-down decisions. At Step 5, show a branching pathway for biologics selection based on phenotype (eosinophilic, allergic, non-T2). Include assessment boxes between steps showing: symptom control, exacerbation risk, lung function, and adherence check.</image>

Assessment and Monitoring

Asthma Control Assessment

Asthma control is assessed across two dimensions: symptom control and future risk. Symptom control over the preceding 4 weeks evaluates four domains: daytime symptoms occurring more than twice per week, nighttime awakening due to asthma, reliever use more than twice per week, and any activity limitation attributable to asthma. Well-controlled asthma is defined as the absence of all four indicators, partly controlled asthma requires one or two indicators present, and uncontrolled asthma requires three or four. Validated questionnaires provide standardized, reproducible assessments: the Asthma Control Test (ACT) yields a score less than or equal to 19 indicating uncontrolled disease and 20 or above indicating well-controlled disease, while the Asthma Control Questionnaire (ACQ) uses a threshold of 1.5 or greater to identify uncontrolled asthma.

Risk Factors for Exacerbation

Identifying risk factors for future exacerbations is as important as assessing current symptom control. Prior ICU admission or intubation for asthma constitutes the strongest predictor of future near-fatal or fatal events. One or more exacerbations in the preceding 12 months identifies the frequent exacerbator phenotype. Poor medication adherence and incorrect inhaler technique, affecting up to 80% of patients in some studies, are among the most common modifiable risk factors. High SABA use, defined as three or more canisters per year, has been identified as an independent risk factor for increased mortality in the global SABINA programme. Comorbidities including gastroesophageal reflux disease, chronic rhinosinusitis, obesity, depression, and food allergy each contribute to poor asthma control and increased exacerbation risk. Persistently elevated biomarkers, including FeNO, blood eosinophils, or sputum eosinophils despite current treatment, suggest ongoing uncontrolled inflammation.

Acute Asthma Management

Severity Assessment

Rapid severity assessment guides the intensity of acute management. Mild-to-moderate exacerbations are characterized by the ability to speak in phrases, absence of agitation, elevated respiratory rate without accessory muscle use, SpO2 between 90% and 95%, and PEF above 50% of predicted or personal best. Severe exacerbations present with the patient speaking in single words, sitting hunched forward, respiratory rate above 30, active accessory muscle use, SpO2 below 90%, and PEF at or below 50% predicted. Life-threatening features include drowsiness or confusion, silent chest on auscultation, central cyanosis, bradycardia, and PEF below 25% predicted, mandating immediate intervention and consideration of ICU transfer.

Acute Management Protocol

The management of acute asthma follows a systematic escalation protocol. High-flow oxygen should be administered to target SpO2 of 93-95%. Continuous nebulized salbutamol at 5 mg every 20 minutes for three doses, followed by every 1 to 4 hours as needed, constitutes the initial bronchodilator therapy. Metered-dose inhaler delivery of 4 to 8 puffs every 20 minutes via spacer is equally effective when adequate technique is achievable. Ipratropium bromide 500 mcg nebulized every 20 minutes for three doses is added for severe exacerbations, where the combination produces greater bronchodilation than beta-agonist alone. Systemic corticosteroids should be administered promptly, with prednisone 40-50 mg orally or methylprednisolone 125 mg intravenously, continued for 5 to 7 days. No taper is necessary for courses lasting 7 days or less. Intravenous magnesium sulfate, 2 grams infused over 20 minutes, is reserved for severe and life-threatening exacerbations, with the MAGNETIC trial supporting its efficacy in the severe subgroup. Intravenous aminophylline should be considered only for refractory cases, given its narrow therapeutic index and limited evidence of benefit. If intubation becomes necessary, ketamine is the preferred induction agent due to its bronchodilating properties, and ventilator settings should employ a low respiratory rate with prolonged expiratory time to minimize dynamic hyperinflation.

<image>An emergency department clinical pathway for acute asthma exacerbation management. Start with initial assessment (vital signs, PEF, SpO2, work of breathing). Branch into mild-moderate and severe pathways. Show medication doses and timing at each stage: SABA dosing, ipratropium addition, systemic steroids, magnesium sulfate threshold. Include reassessment points at 1 hour and 4 hours with decision nodes for discharge vs. admission vs. ICU. Show discharge criteria (PEF > 70%, stable on q4h bronchodilators, adequate home medications) and discharge medications. Use red flags for life-threatening features requiring immediate ICU consultation.</image>

Non-Pharmacologic Management

Trigger Avoidance and Environmental Control

Non-pharmacologic interventions are essential complements to medical therapy. Allergen avoidance strategies should be guided by the patient's sensitization profile as determined by skin prick testing or specific IgE measurement. Smoking cessation is imperative, as smoking accelerates FEV1 decline in asthma and reduces the efficacy of inhaled corticosteroids. Weight loss in obese asthmatics, targeting a 5-10% reduction in body weight, has been shown to improve asthma control, as demonstrated in the LOOSE trial. Occupational asthma requires early identification and removal from the offending exposure, as delayed removal leads to persistent, irreversible disease. Regular aerobic exercise improves asthma control and should be encouraged in all patients, with pretreatment using SABA or ICS-formoterol recommended for those with exercise-induced bronchoconstriction.

Comorbidity Management

Systematic management of comorbidities is essential for achieving optimal asthma control. Gastroesophageal reflux disease should be treated when symptomatic, but routine use of proton pump inhibitors does not improve asthma outcomes in the absence of GERD symptoms, as demonstrated by the SARA trial. Rhinosinusitis is managed with intranasal corticosteroids, reflecting the unified airway concept in which upper and lower airway inflammation are pathophysiologically linked. Anxiety and depression should be actively screened for and treated, as they are associated with poor medication adherence and symptom overreporting, both of which complicate clinical management. Obstructive sleep apnea, when identified and treated with continuous positive airway pressure, may independently improve asthma control.

Key Clinical Pearls

• SABA-only treatment is no longer recommended at any step of asthma management per GINA 2024 - every patient should have access to ICS
• Overuse of SABA (>= 3 canisters/year) is an independent predictor of asthma-related mortality
• Before stepping up therapy, always check: inhaler technique, adherence, ongoing trigger exposure, and comorbidities
• Normal spirometry does not exclude asthma; bronchoprovocation testing or PEF variability monitoring may be required
• Near-fatal asthma risk factors include prior intubation, psychiatric comorbidity, psychosocial dysfunction, and food allergy (anaphylaxis overlap)

References

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024. Available at: www.ginasthma.org.
2. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018;378(20):1865-1876. (SYGMA 1)
3. Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919-928.
4. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022;205(1):17-35.
5. Nwaru BI, Ekstr M, Hasvold P, et al. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872.

Read this lecture as Markdown